Joel Isaacson & Co. LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 1.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 52,369 shares of the biopharmaceutical company’s stock after selling 835 shares during the quarter. Joel Isaacson & Co. LLC’s holdings in Pfizer were worth $2,137,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. RB Capital Management LLC raised its holdings in Pfizer by 6.7% during the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 341 shares during the period. Ironwood Wealth Management LLC. raised its holdings in shares of Pfizer by 1.1% during the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after acquiring an additional 400 shares in the last quarter. United Bank lifted its holdings in shares of Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after buying an additional 290 shares during the last quarter. Ergoteles LLC lifted its stake in Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after acquiring an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp boosted its holdings in Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after purchasing an additional 79,887 shares in the last quarter. 67.80% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
PFE has been the subject of several recent analyst reports. Wells Fargo & Company decreased their price objective on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating for the company in a report on Friday, March 17th. Daiwa Capital Markets cut Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 price objective on the stock. in a research report on Thursday, May 11th. UBS Group dropped their price target on shares of Pfizer from $41.00 to $39.00 in a research report on Friday, May 5th. Bank of America cut their price objective on Pfizer from $50.00 to $45.00 and set a “neutral” rating for the company in a report on Friday, April 21st. Finally, Barclays cut their target price on shares of Pfizer from $43.00 to $40.00 in a research note on Wednesday, May 3rd. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $46.67.
Insider Activity at Pfizer
Pfizer Price Performance
PFE opened at $35.53 on Monday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.11 and a current ratio of 1.37. Pfizer Inc. has a 52 week low of $35.35 and a 52 week high of $54.93. The company has a fifty day moving average price of $38.03 and a two-hundred day moving average price of $41.50. The firm has a market capitalization of $200.58 billion, a PE ratio of 6.99, a P/E/G ratio of 1.18 and a beta of 0.61.
Pfizer (NYSE:PFE – Free Report) last issued its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.00 by $0.23. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The firm had revenue of $18.28 billion during the quarter, compared to the consensus estimate of $16.49 billion. During the same quarter in the prior year, the firm earned $1.62 earnings per share. The business’s quarterly revenue was down 28.8% on a year-over-year basis. As a group, analysts anticipate that Pfizer Inc. will post 3.35 earnings per share for the current year.
Pfizer Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th will be issued a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a dividend yield of 4.62%. The ex-dividend date is Thursday, July 27th. Pfizer’s dividend payout ratio (DPR) is presently 32.28%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
- Five stocks we like better than Pfizer
- MarketBeat Week in Review – 7/3 – 7/7
- Pfizer Just Invested $25 million In This Biotech
- Cracks In The Labor Market? Not Yet, But They’re Coming
- Levi’s: Buy On The Dip Or Downtrend In Play?
- Who Wins And Who Loses With China’s Metal Restrictions
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
